Chronic Fatigue Syndrome Solutions
CF Support Scientific Review Chronic Fatigue Pharmacy Testimonials
homeChronic Fatigue Symtomsproduct descriptioncontact usBuy CF Solution
CF Support Scientific Review



Possible side effects include stomach irritation, anxiety, irritability and insomnia.   Pregnant and breast-feeding women are advised to consult their healthcare practitioner before using CF Support.

This product is not suitable for persons allergic to bovine products.   There is no known drug interaction.

Suggested Use

As a dietary supplement, take one bottle of NatCell® CF Support per day.  Start with CF Supportl for 8 days, then CF Support2 for 8 days and finish the cycle with CF Support1 for 8 days.   CF Support1 contains 5.6 ml of bovine mesenchyme aqueous extract, and 1.4 ml of bovine adrenal aqueous extract. CF Support2 contains 3.5 ml of bovine mesenchyme aqueous extract, and 3.5 ml of bovine adrenal aqueous extract. Serving size: 1 bottle of 7 ml.


- Behan WM, More IA, Behan PO., Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol (Berl). 1991;83(1):61-5.

- Bennett RM, Adult growth hormone deficiency in patients with fibromyalgia. Curr Rheumatol Rep. 2002 Aug;4(4):306-12. Review

- Berwaerts J, Moorkens G, Abs R., Secretion of growth hormone in patients with chronic fatigue syndrome. Growth Horm IGF Res. 1998 Apr;8 Suppl B:127-9.

- Buchwald D, Herrell R, Ashton S, Belcourt M, Schmaling K, Sullivan P, Neale M, Goldberg J., A twin study of chronic fatigue. Psychosom Med, 2001 Nov-Dec;63(6):936-43.

- Craveri F, De Pascale V., Activity of orally administered adrenocortical extract. 1. Effect on the survival test. Boll Chim Farm 1971;110:457-62.

- Craveri F, De Pascale V., Activity of orally administered adrenocortical extract. II. Effect on liver glycogenesis and sodium retention. Boll Chim Farm 1971;110:457-62.

- Craveri F, De Pascale V., Activity of orally administered adrenocortical extract. III. Effect in tests based on muscular work. Boll Chim Farm 1971; 110: 457-62.

- DeMeirleir K, Bisbal C, Campine I, De Becker, P, Salehzada, T, Demettre, E and Lebleu, BA., A 37 kDa 25A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med, 2000; (108);99-105

- Demitrack MA Crofford W., Evidence for and pathophysiologic implications of hypothalamicpituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann N Y Acad Sci. 1998 May 1;840:684-97. Review.

- Dowsett EG, Ramsay AM, McCartney RA, Bell EJ., Myalgic encephalomyelitis--a persistent enteroviral infection? Postgrad Med J. 1990 Jul;66(777):526-30.

- Farrar DJ, Locke SE, Kantrowitz FG, Chronic Fatigue Syndrome.1: Etiology and Pathogenesis Behavioral Medicine, 1995; 21 (1): 5-16

- Fulle S, Mecocci P, Fano G, Vecchiet I, Vecchini A, Racciotti D, Cherubini A, Pizzigallo E, Vecchiet L, Senin U, Beal MF., Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med. 2000 Dec 15;29(12):1252-9.

- Gaab J, Huster D, Peisen R, Engert V, Schad T, Schurmeyer TH, Ehlert U, Low-dose dexamethasone suppression test in chronic fatigue syndrome and health. Psychosom Med. 2002 Mar-Apr;64(2):311-8.

- Ho-Yen DO, McNamara I., General practitioners' experience of the chronic fatigue syndrome. Br J Gen Pract. 1991; Aug;41(349):324-6.

- Katon W, Walker E., The relationship of chronic fatigue to psychiatric illness in community, primary care and tertiary care samples.- Chronic fatigue syndrome- New York: Wiley, John & Sons Inc. 1993, Ciba Foundation Symposia Series; no 173: 193-211

- Keller RH, Lane JL, Klimas N, Reiter WM, Fletcher MA, van Riel F, Morgan R., Association of HLA class II antigens and chronic fatigue immune dysfunction syndrome. Clin Infect Dis, 1994; (18): S154-6

- Klein R, Berg PA, High incidence of antibodies to 5-hydroxy-tryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. Eur J Med Res, 1995; (1):21-6

- Landay AL, Jessop C, Lennette ET, Levyk JA, Chronic Fatigue Syndrome: clinical condition associated with immune activation. Lancet, 1991; (338) no 8769:707-12

- Lane RJ, Barrett MC, Woodrow D, Moss J, Fletcher R, Archard LC., Muscle fibre characteristics and lactate responses to exercise in chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):362-7.

- Levine PH, Whiteside TL, Friberg D, Bryant J, Colclough G, Herberman RB, Dysfunction of natural killer activity in a family with chronic fatigue syndrome. Clin Immunol Immunopathol, 1998; (88):96-104

- Leal-Cerro A, Povedano J, Astorga R, Gonzalez M, Silva H, Garcia-Pesquera F, Casanueva FF, Dieguez C., The growth hormone (GH)-releasing hormone-GH-insulin-like growth factor-1 axis in patients with fibromyalgia syndrome. J Clin Endocrinol Metab. 1999 Sep;84(9):3378-81.

- Logan AC, Wong C., Chronic fatigue syndrome: oxidative stress and dietary modifications. Altern Med Rev. 2001 Oct;6(5):450-9. Review.

- MacHale SM, Cavanagh JT, Bennie J, Carroll S, Goodwin GM, Lawrie SM., Diurnal variation of adrenocortical activity in chronic fatigue syndrome. Neuropsychobiology. 1998 Nov;38(4):213-7.

- Manian FA, Simultaneous measurement of antibodies to Epstein-Barr virus, human herpesvirus 6, herpes simplex virus types 1 and 2, and 14 enteroviruses in chronic fatigue syndrome: is there evidence of activation of a nonspecific polyclonal immune response? Clin Infect Dis. 1994 Sep;19(3):448-53.

- McCully KK, Natelson BH, Iotti S, Sisto S, Leigh JS Jr., Reduced oxidative muscle metabolism in chronic fatigue syndrome. Muscle Nerve. 1996 May; 19(5):621-5.

- Niehans P., Introduction to cellular therapy. New York, NY. Pageant books, 1960.

- Ottenweller JE, Sisto SA, McCarty RC, Natelson BH., Hormonal responses to exercise in chronic fatigue syndrome. Neuropsychobiology. 2001 Jan;43(l):34-41.

- Richards RS, Roberts TK, McGregor NR, Dunstan RH, Butt HL., Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep. 2000;5(l):35-41.

- Shepherd C., Hydrocortisone and chronic fatigue syndrome. Lancet. 1999 May 8;353(9164):161920.

- Scott LV, Teh J, Reznek R, Martin A, Sohaib A, Dinan TG, Small adrenal glands in chronic fatigue syndrome: a preliminary computer tomography study. Psychoneuroendocrinology, 1999; (24): 75968

- Scott LV, Medbak S, Dinan TG., Blunted adrenocorticotropin and cortisol -responses to cortocotropic-releasing hormone stimulation in chronic fatigue syndrome. Acta Psychiatr Scand 1998;97:450-457.

- US Department of Health and Human Services. National Center for Infectuous diseases. Centers for Disease Control and Prevention. The facts about chronic fatigue syndrome, Atlanta, GA, 1995.

- Walsh CM, Zainal NZ, Middleton SJ, Paykel ES., A family history study of chronic fatigue syndrome. Psychiatr Genet, 2001; Sep;11(3):123-8.

- Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J., Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol, 1997; (24):555-9

<:::Back   |   Table of Contents   |   Next:::>

2003 Atrium Biotechnologies Inc. All Rights Reserved 4/19
©CF Support Scientific Review


Search This Site's Archives for


© Chronic Fatigue Solution